L51.3 Stevens-Johnson syndrome-toxic epidermal necrolysis overlap syndrome

Name of the Condition

• Stevens-Johnson syndrome-toxic epidermal necrolysis overlap syndrome

Summary

Stevens-Johnson syndrome-toxic epidermal necrolysis (SJS-TEN) overlap syndrome is a severe skin and mucous membrane disorder characterized by widespread blistering, skin detachment, and systemic involvement. It represents a continuum between Stevens-Johnson syndrome and toxic epidermal necrolysis, with significant morbidity and potential mortality requiring urgent medical intervention.

Causes

Most commonly caused by adverse reactions to medications, such as antibiotics, anticonvulsants, or nonsteroidal anti-inflammatory drugs. Infections, particularly herpes simplex virus or Mycoplasma pneumoniae, can also trigger SJS-TEN overlap. The condition involves immune-mediated damage to skin and mucous membranes.

Risk Factors

• Use of certain medications, especially those known to cause hypersensitivity reactions.
• Recent infections, particularly viral or bacterial infections.
• A history of prior drug reactions or genetic predisposition to severe cutaneous adverse reactions.

Symptoms

• Rapid onset of red or purplish skin rash, often with blistering.
• Painful skin detachment or sloughing, typically affecting 10-30% of body surface area.
• Mucous membrane involvement, including mouth, eyes, or genital areas, leading to pain or difficulty eating.

Diagnosis

Diagnosis is primarily clinical, based on the characteristic skin and mucous membrane findings. A detailed patient history, including medication use and recent infections, is essential. Skin biopsy may be performed to confirm the diagnosis and rule out other conditions. The extent of skin detachment is assessed to determine the severity.

Treatment Options

• Immediate discontinuation of suspected causative medications.
• Supportive care in a burn or intensive care unit, including fluid replacement and infection prevention.
• Systemic corticosteroids or intravenous immunoglobulin may be used in some cases, though evidence is mixed.
• Management of pain, eye care, and nutritional support as needed.

Prognosis and Follow-Up

Prognosis depends on the extent of skin detachment and systemic involvement. Mortality can occur, particularly with extensive skin loss or organ involvement. Long-term follow-up is necessary to monitor for complications, such as scarring, eye damage, or psychological effects. Recovery may take weeks to months.

Complications

• Secondary infections due to skin barrier disruption.
• Permanent scarring or skin discoloration.
• Eye complications, including dryness, vision impairment, or blindness.
• Respiratory or gastrointestinal involvement in severe cases.
• Psychological impact, such as anxiety or depression.

Lifestyle & Prevention

• Avoid known trigger medications and inform healthcare providers of drug allergies.
• Promptly report new rashes or symptoms after starting a new medication.
• Maintain good hygiene to reduce infection risk during recovery.
• Use sunscreen and protective clothing to prevent skin damage.

When to Seek Professional Help

Seek immediate medical attention if you experience:

• Rapidly spreading rash with blistering or skin peeling.
• Painful mouth sores or difficulty swallowing.
• Fever, fatigue, or signs of systemic illness.
• Eye redness, pain, or vision changes.

Tips for Medical Coders

Document the extent of skin detachment (e.g., percentage of body surface area) and any mucous membrane involvement, as these details support the diagnosis. Note causative factors, such as medication use or infection, and any systemic complications. Ensure clinical correlation with the characteristic findings of SJS-TEN overlap to confirm the code assignment.